Leading Biotechnology Alliances : Right from the Start

個数:

Leading Biotechnology Alliances : Right from the Start

  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6~9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 204 p.
  • 言語 ENG
  • 商品コード 9780471182481
  • DDC分類 660.60681

Full Description

Since the early 1990s, research and discovery collaborations between biotechnology and pharmaceutical companies have increased to the point that they now provide more than half of the total capital invested in the biotechnology sector. Although smaller biotechnology companies may be engaged in only a few alliances at a time, some of the most active pharmaceutical players may be engaged in anywhere from thirty to forty alliances at once. Any single alliance relationship may be the lifeblood for a small biotechnology company, while the same relationship may be just one of many for the pharmaceutical partner.
Research alliances with small, close-to-the-science companies are the source of many of the innovative ideas of today and the future, but they present formidable challenges. Successful collaboration depends not only on the solution of scientific and technical problems, but also on the successful resolution of many leadership and organizational problems.
Leading Biotechnology Alliances presents a tightly focused discussion regarding issues and questions that are unique and critical to the effectiveness of alliances, including:
* Power differences and other asymmetries between partner firms and some implications for alliance dynamics
* Sector history and evolution as a basis for understanding the cultural divide that characterizes many biotechnology-pharmaceutical relationships
* Why leaders on the biotechnology side must assume the greater leadership responsibility in these alliances
* Different - and predictable - challenges over the alliance life cycle, from start to completion/termination
* Leadership roles needed for productive and effective collaboration across groups, locations, and companies
From societal and economic perspectives, it is important to lead biotechnology alliances right, right from the start. The intent of Leading Biotechnology Alliances is to help scientists and executives from large and small companies do just that - collaborate productively and effectively. This book includes a case study, numerous interview excerpts, general theory and background, a delineation of alliance responsibilities, and a set of alliance effectiveness questions. Together, these ingredients provide the reader with a clear understanding of the complicated dynamics of alliances and leadership issues and roles within the alliance life cycle.

Contents

TROUBLE IN ALLIANCE LAND.

A Case in Point: The Lucida-Pharma Alliance Cast of Characters.

The General Case: Many Alliances, Many Problems.

ASYMMETRIC RELATIONSHIPS, LOPSIDED RESPONSIBILITY.

Contrasting Cultures.

Partner Differences and Disparities.

LAYING THE GROUNDWORK.

Preparing the Organization.

Individual and Organizational Due Diligence.

The First Meetings.

THE ALLIANCE LIFE CYCLE: LEADING DIFFERENTLY OVER TIME.

To the First Milestone.

Managing Growth and Maturity.

Ending: Completion, or Termination.

Readiness, Learning, and Alliance Effectiveness: A Road Map.

If We Could Turn Back the Clock...(A Hypothetical Coda to the Lucida-Pharma Sciences Case).